Hiroki Hara Selected Research

Hiroki Hara Research Topics

Disease

32	Neoplasms (Cancer) 10/2022 - 09/2008
23	Stomach Neoplasms (Stomach Cancer) 01/2022 - 09/2008
19	Esophageal Squamous Cell Carcinoma 10/2022 - 11/2013
17	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 12/2014
10	Disease Progression 01/2022 - 02/2014
9	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2015
8	Esophageal Neoplasms (Esophageal Cancer) 10/2022 - 01/2019
7	Adenocarcinoma 10/2022 - 01/2017
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2022 - 11/2016
5	Infections 02/2021 - 06/2002
5	Neutropenia 02/2021 - 11/2013
4	Microsatellite Instability 01/2022 - 12/2014
4	Carcinoma (Carcinomatosis) 07/2020 - 07/2016
3	Pancreatic Neoplasms (Pancreatic Cancer) 02/2021 - 01/2016
3	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2018 - 02/2014
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022 - 01/2022
2	Squamous Cell Carcinoma of Head and Neck 01/2022 - 01/2022
2	Febrile Neutropenia 02/2021 - 01/2017
2	Leukopenia 01/2021 - 01/2019
2	Ascites 01/2020 - 04/2018
2	Anorexia 01/2019 - 11/2013
2	Pneumonia (Pneumonitis) 01/2017 - 10/2011
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2020
1	Pulmonary Tuberculosis 01/2020
1	Pancreatitis 01/2020
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2020

Drug/Important Bio-Agent (IBA)

16	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 11/2013
14	Fluorouracil (Carac)FDA LinkGeneric 01/2022 - 11/2013
10	Docetaxel (Taxotere)FDA Link 10/2022 - 11/2013
9	PlatinumIBA 01/2022 - 08/2013
9	NivolumabIBA 01/2022 - 01/2017
8	pembrolizumabIBA 10/2022 - 01/2019
7	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 01/2017
6	Cetuximab (Erbitux)FDA Link 06/2022 - 01/2018
5	Leucovorin (Folinic Acid)FDA Link 11/2021 - 04/2018
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2021 - 01/2020
4	Irinotecan (Camptosar)FDA LinkGeneric 10/2022 - 01/2020
3	B7-H1 AntigenIBA 10/2022 - 01/2021
3	human ERBB2 proteinIBA 06/2022 - 08/2017
3	trifluridine tipiracil drug combinationIBA 01/2022 - 11/2020
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2014
3	regorafenibIBA 01/2022 - 01/2020
3	Monoclonal AntibodiesIBA 01/2022 - 01/2019
3	130-nm albumin-bound paclitaxelIBA 08/2021 - 01/2017
3	Gemcitabine FDA Link 02/2021 - 01/2016
3	Trastuzumab (Herceptin)FDA Link 02/2020 - 08/2013
3	Alanine Transaminase (SGPT)IBA 01/2020 - 10/2011
3	Pharmaceutical PreparationsIBA 01/2020 - 09/2008
2	Programmed Cell Death 1 ReceptorIBA 10/2022 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2020
2	AntibodiesIBA 01/2022 - 06/2002
2	Taxoids (Taxanes)IBA 01/2022 - 03/2021
2	ErbB Receptors (EGF Receptor)IBA 01/2022 - 08/2013
2	Platinum Compounds (Compounds, Platinum)IBA 01/2022 - 07/2020
2	Circulating Tumor DNAIBA 01/2022 - 10/2021
2	taxaneIBA 07/2021 - 01/2017
2	RamucirumabIBA 07/2021 - 07/2020
2	HLA Antigens (Human Leukocyte Antigens)IBA 05/2020 - 04/2020
2	Everolimus FDA Link 01/2020 - 02/2014
2	CreatinineIBA 10/2018 - 01/2017
1	tislelizumabIBA 10/2022
1	Notch ReceptorsIBA 10/2022
1	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 06/2022
1	durvalumabIBA 01/2022
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	lenvatinibIBA 01/2022
1	tremelimumabIBA 01/2022
1	Formaldehyde (Formol)FDA Link 01/2022
1	CTLA-4 AntigenIBA 01/2022
1	Hematoxylin (Haematoxylon)IBA 01/2022
1	ParaffinIBA 01/2022
1	Capecitabine (Xeloda)FDA Link 08/2021
1	pevonedistatIBA 08/2021
1	EnzymesIBA 08/2021
1	IpilimumabIBA 02/2021
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 02/2021
1	Fenofibrate (CiL)FDA LinkGeneric 01/2021
1	fms-Like Tyrosine Kinase 3IBA 01/2021
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2021
1	napabucasinIBA 11/2020
1	atezolizumabIBA 04/2020
1	pertuzumabIBA 02/2020
1	S-1 plus cisplatinIBA 01/2020
1	Lipase (Acid Lipase)FDA Link 01/2020
1	Panitumumab (Vectibix)FDA Link 01/2020

Therapy/Procedure

44	Drug Therapy (Chemotherapy) 10/2022 - 09/2008
15	Therapeutics 06/2022 - 02/2014
8	Chemoradiotherapy 01/2022 - 07/2016
6	Induction Chemotherapy 02/2021 - 07/2016
4	Adjuvant Chemotherapy 01/2019 - 12/2014
3	Radiotherapy 01/2019 - 11/2015
2	Immunotherapy 01/2022 - 04/2020
2	Neoadjuvant Therapy 07/2020 - 09/2008
1	Molecular Targeted Therapy 01/2022
1	Precision Medicine 01/2022
1	Combination Drug Therapy (Combination Chemotherapy) 07/2021
1	Salvage Therapy 10/2020